Samsca is a drug owned by Otsuka Pharmaceutical Co Ltd. It is protected by 4 US drug patents filed from 2013 to 2021. Out of these, 2 drug patents are active and 2 have expired. Samsca's patents have been open to challenges since 19 May, 2013. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 07, 2030. Details of Samsca's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US8501730 | Process for preparing benzazepine compounds or salts thereof |
Sep, 2026
(5 months from now) | Active |
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10905694 | Pharmaceutical solid preparation comprising benzazepines and production method thereof |
Apr, 2030
(4 years from now) | Active |
| US5753677 | Benzoheterocyclic compounds |
May, 2015
(10 years ago) |
Expired
|
| US5258510 | Benzoheterocyclic compounds |
Nov, 2012
(13 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Samsca's patents.
Latest Legal Activities on Samsca's Patents
Given below is the list of recent legal activities going on the following patents of Samsca.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 18 Dec, 2024 | US8501730 (Litigated) |
| Payment of Maintenance Fee, 4th Year, Large Entity | 17 Jul, 2024 | US10905694 |
| Patent Issue Date Used in PTA Calculation | 02 Feb, 2021 | US10905694 |
| Recordation of Patent Grant Mailed | 02 Feb, 2021 | US10905694 |
| Email Notification | 14 Jan, 2021 | US10905694 |
| Issue Notification Mailed | 13 Jan, 2021 | US10905694 |
| Application Is Considered Ready for Issue | 28 Dec, 2020 | US10905694 |
| Dispatch to FDC | 28 Dec, 2020 | US10905694 |
| Issue Fee Payment Received | 23 Dec, 2020 | US10905694 |
| Issue Fee Payment Verified | 23 Dec, 2020 | US10905694 |
FDA has granted several exclusivities to Samsca. Till the time
these exclusivities
are active, no other company can market a generic or bioequivalent version of Samsca, regardless of the status of it's patents. These exclusivities hence play a crucial role in
delaying the generic
launch. Given below are details of the exclusivities granted to
Samsca.
Exclusivity Information
Samsca holds 1 exclusivities. All of its exclusivities have expired in 2014. Details of Samsca's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 19, 2014 |
US patents provide insights into the exclusivity only within the United States, but
Samsca is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Samsca's family patents as well as insights into
ongoing legal events
on those patents.
Samsca's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Samsca's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Apr 07, 2030 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Samsca Generic API suppliers:
Tolvaptan is the generic name for the brand Samsca. 6 different companies have already filed for the generic of Samsca, with Apotex having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Samsca's generic
How can I launch a generic of Samsca before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Samsca's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Samsca's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Samsca -
| Strength | Submission Date | Expiration Date of Last Qualifying Patent | 180-Day Status | First Applicant Approval | Generic Competition Status |
|---|---|---|---|---|---|
| 26 Mar, 2018 | 01 Sep, 2026 | Eligible | 19 May, 2020 | Less | |
| 10 Oct, 2013 | 01 Sep, 2026 | Non-Forfeiture | 15 Feb, 2022 | Less | |
| 23 Sep, 2013 | 19 May, 2020 | Extinguished Non-Forfeiture | Less |
Alternative Brands for Samsca
Samsca which is used for treating low levels of sodium in the blood (hyponatremia)., has several other brand drugs using the same active ingredient (Tolvaptan). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Otsuka |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Tolvaptan, Samsca's active ingredient. Check the complete list of approved generic manufacturers for Samsca
About Samsca
Samsca is a drug owned by Otsuka Pharmaceutical Co Ltd. It is used for treating low levels of sodium in the blood (hyponatremia). Samsca uses Tolvaptan as an active ingredient. Samsca was launched by Otsuka in 2009.
Approval Date:
Samsca was approved by FDA for market use on 19 May, 2009.
NCE-1 date:
NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Samsca is 19 May, 2009, its NCE-1 date is estimated to be 19 May, 2013.
Active Ingredient:
Samsca uses Tolvaptan as the active ingredient. Check out other Drugs and Companies using Tolvaptan ingredient
Treatment:
Samsca is used for treating low levels of sodium in the blood (hyponatremia).
Dosage:
Samsca is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 60MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET | Discontinued | ORAL |
| 15MG | TABLET | Prescription | ORAL |
| 30MG | TABLET | Prescription | ORAL |